322 related articles for article (PubMed ID: 16109584)
1. The acute anti-craving effect of acamprosate in alcohol-preferring rats is associated with modulation of the mesolimbic dopamine system.
Cowen MS; Adams C; Kraehenbuehl T; Vengeliene V; Lawrence AJ
Addict Biol; 2005 Sep; 10(3):233-42. PubMed ID: 16109584
[TBL] [Abstract][Full Text] [Related]
2. The glycine reuptake inhibitor Org24598 and acamprosate reduce ethanol intake in the rat; tolerance development to acamprosate but not to Org24598.
Lidö HH; Marston H; Ericson M; Söderpalm B
Addict Biol; 2012 Sep; 17(5):897-907. PubMed ID: 21955180
[TBL] [Abstract][Full Text] [Related]
3. Effect of chronic acamprosate treatment on voluntary alcohol intake and beta-endorphin plasma levels in rats selectively bred for high alcohol preference.
Zalewska-Kaszubska J; Górska D; Dyr W; Czarnecka E
Neurosci Lett; 2008 Feb; 431(3):221-5. PubMed ID: 18162308
[TBL] [Abstract][Full Text] [Related]
4. Glycine receptors in the nucleus accumbens involved in the ethanol intake-reducing effect of acamprosate.
Chau P; Höifödt-Lidö H; Löf E; Söderpalm B; Ericson M
Alcohol Clin Exp Res; 2010 Jan; 34(1):39-45. PubMed ID: 19860809
[TBL] [Abstract][Full Text] [Related]
5. Effects of acamprosate on ethanol-seeking and self-administration in the rat.
Czachowski CL; Legg BH; Samson HH
Alcohol Clin Exp Res; 2001 Mar; 25(3):344-50. PubMed ID: 11290844
[TBL] [Abstract][Full Text] [Related]
6. Glycine receptors involved in acamprosate's modulation of accumbal dopamine levels: an in vivo microdialysis study.
Chau P; Stomberg R; Fagerberg A; Söderpalm B; Ericson M
Alcohol Clin Exp Res; 2010 Jan; 34(1):32-8. PubMed ID: 19860810
[TBL] [Abstract][Full Text] [Related]
7. Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release.
Olive MF; Nannini MA; Ou CJ; Koenig HN; Hodge CW
Eur J Pharmacol; 2002 Feb; 437(1-2):55-61. PubMed ID: 11864639
[TBL] [Abstract][Full Text] [Related]
8. Metabotropic glutamate receptor 5 (mGluR5) regulation of ethanol sedation, dependence and consumption: relationship to acamprosate actions.
Blednov YA; Harris RA
Int J Neuropsychopharmacol; 2008 Sep; 11(6):775-93. PubMed ID: 18377703
[TBL] [Abstract][Full Text] [Related]
9. Changes in the beta-endorphin plasma level after repeated treatment with acamprosate in rats selectively bred for high and low alcohol preference.
Zalewska-Kaszubska J; Cwiek W; Dyr W; Czarnecka E
Neurosci Lett; 2005 Nov; 388(1):45-8. PubMed ID: 16009491
[TBL] [Abstract][Full Text] [Related]
10. Time course of acamprosate action on operant ethanol self-administration after ethanol deprivation.
Hölter SM; Landgraf R; Zieglgänsberger W; Spanagel R
Alcohol Clin Exp Res; 1997 Aug; 21(5):862-8. PubMed ID: 9267536
[TBL] [Abstract][Full Text] [Related]
11. Acamprosate for the treatment of alcohol dependence.
Boothby LA; Doering PL
Clin Ther; 2005 Jun; 27(6):695-714. PubMed ID: 16117977
[TBL] [Abstract][Full Text] [Related]
12. Repeated alcohol administration during adolescence causes changes in the mesolimbic dopaminergic and glutamatergic systems and promotes alcohol intake in the adult rat.
Pascual M; Boix J; Felipo V; Guerri C
J Neurochem; 2009 Feb; 108(4):920-31. PubMed ID: 19077056
[TBL] [Abstract][Full Text] [Related]
13. Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators.
Ooteman W; Naassila M; Koeter MW; Verheul R; Schippers GM; Houchi H; Daoust M; van den Brink W
Addict Biol; 2009 Jul; 14(3):328-37. PubMed ID: 19523047
[TBL] [Abstract][Full Text] [Related]
14. Alterations in central preproenkephalin mRNA expression after chronic free-choice ethanol consumption by fawn-hooded rats.
Cowen MS; Lawrence AJ
Alcohol Clin Exp Res; 2001 Aug; 25(8):1126-33. PubMed ID: 11505043
[TBL] [Abstract][Full Text] [Related]
15. Naltrexone suppresses ethanol intake in 6-hydroxydopamine-treated rats.
Koistinen M; Tuomainen P; Hyytiä P; Kiianmaa K
Alcohol Clin Exp Res; 2001 Nov; 25(11):1605-12. PubMed ID: 11707635
[TBL] [Abstract][Full Text] [Related]
16. Acamprosate's ethanol intake-reducing effect is associated with its ability to increase dopamine.
Chau P; Lidö HH; Söderpalm B; Ericson M
Pharmacol Biochem Behav; 2018 Dec; 175():101-107. PubMed ID: 30266455
[TBL] [Abstract][Full Text] [Related]
17. Effects of repeated cocaine treatment on striatal dopamine release in alcohol-preferring AA and alcohol-avoiding ANA rats.
Mikkola JA; Honkanen A; Piepponen TP; Kiianmaa K; Ahtee L
Naunyn Schmiedebergs Arch Pharmacol; 2001 Feb; 363(2):209-14. PubMed ID: 11218073
[TBL] [Abstract][Full Text] [Related]
18. The metabotropic glutamate 5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine reduces ethanol self-administration in multiple strains of alcohol-preferring rats and regulates olfactory glutamatergic systems.
Cowen MS; Djouma E; Lawrence AJ
J Pharmacol Exp Ther; 2005 Nov; 315(2):590-600. PubMed ID: 16014750
[TBL] [Abstract][Full Text] [Related]
19. Acamprosate produces its anti-relapse effects via calcium.
Spanagel R; Vengeliene V; Jandeleit B; Fischer WN; Grindstaff K; Zhang X; Gallop MA; Krstew EV; Lawrence AJ; Kiefer F
Neuropsychopharmacology; 2014 Mar; 39(4):783-91. PubMed ID: 24081303
[TBL] [Abstract][Full Text] [Related]
20. Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification.
Wilde MI; Wagstaff AJ
Drugs; 1997 Jun; 53(6):1038-53. PubMed ID: 9179530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
